ARTICLE | Product Development

Ion channel blocker for cancer

August 16, 2004 7:00 AM UTC

Ion channel blockers are generally thought of as having utility in CNS indications because they regulate neurons. However, NeuroSearch A/S believes that its Endovion (NS3728) volume regulated anion channel (VRAC) blocker will be useful in cancer because it also has anti-angiogenic properties.

Endovion was originally tested in 2002 in a Phase I trial in adults with sickle cell anemia. But NeuroSearch (CSE:NEUR, Ballerup, Denmark) decided not to pursue the indication because the larger market is in children, and the company concluded it did not have the resources to do the testing required to get a pediatric label. ...